{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:06:29Z","timestamp":1791378389431,"version":"4.3.2"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This study aimed to evaluate the relationship between cardiac toxicity after definitive chemoradiotherapy (CRT) for esophageal cancer and the dose\u2013volume histogram (DVH) of organs at risk (OARs) [using biological effective dose (BED)]. We analyzed the data of 83 patients with esophageal cancer treated using definitive CRT between 2001 and 2016. Furthermore, we evaluated pericardial effusion (PE) as a measure of cardiac toxicity. The median total irradiation dose was 60 (50.4\u201371)\u00a0Gy. Symptomatic PE was observed in 12 (14%) patients. The heart and pericardium V5\u2013V100-BED were significantly higher in patients with symptomatic PE than in those without symptomatic PE (heart: V5\u2013V95-BED, P\u00a0&amp;lt;\u00a00.001; V100-BED, P\u00a0=\u00a00.0053, and pericardium: V5\u2013V40-BED, V55\u2013V95-BED, P\u00a0&amp;lt;\u00a00.001; V45\u201350-BED, V100-BED, P\u00a0&amp;lt;\u00a00.05, respectively). Receiver operating characteristic curve analysis showed that the dose\u2013volume parameter of the pericardium and the heart that was most strongly associated with an adverse cardiac event was V80-BED, and the mean dose and the cut-off value were 27.38% and 61.7\u00a0Gy-BED, respectively. Multivariate analysis showed that the pericardium V80-BED and the mean heart dose-BED were risk factors for symptomatic PE (P\u00a0&amp;lt;\u00a00.001, respectively). We revealed the relationship between the irradiated dose of the OARs and symptomatic PE using a BED-based dose\u2013volume histogram. Pericardium V80-BED and mean heart dose-BED were the most relevant risk factors for symptomatic PE.<\/jats:p>","DOI":"10.1093\/jrr\/rraa001","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T20:10:10Z","timestamp":1579551010000},"page":"298-306","source":"Crossref","is-referenced-by-count":19,"title":["Analysis of cardiac toxicity after definitive chemoradiotherapy for esophageal cancer using a biological dose\u2013volume histogram"],"prefix":"10.1093","volume":"61","author":[{"given":"Yuki","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Kameoka","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ochi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Imano","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuno","family":"Nishibuchi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawahara","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Nagata","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"2020052419000745300_ref1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/jjco\/hyp069","article-title":"A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan clinical oncology group (JCOG9708)","volume":"39","author":"Kato","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"2020052419000745300_ref2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ijrobp.2010.06.033","article-title":"Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II\u2013III esophageal squamous cell carcinoma: JCOG trial (JCOG9906)","volume":"81","author":"Kato","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020052419000745300_ref3","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1200\/JCO.2003.03.055","article-title":"Long term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus","volume":"21","author":"Ishikura","year":"2003","journal-title":"J Clin Oncol"},{"key":"2020052419000745300_ref4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/jrr\/rrw078","article-title":"Long-term complications of definitive chemoradiotherapy for esophageal cancer using classical method","volume":"58","author":"Ito","year":"2017","journal-title":"J Radiat Res"},{"key":"2020052419000745300_ref5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2013.07.008","article-title":"Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients","volume":"87","author":"Fukada","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020052419000745300_ref6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00066-016-0956-1","article-title":"Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer","volume":"192","author":"Ogino","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"2020052419000745300_ref7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.radonc.2014.11.037","article-title":"Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer?","volume":"114","author":"Beukema","year":"2015","journal-title":"Radiother Oncol"},{"key":"2020052419000745300_ref8","first-page":"516","article-title":"Increased risk of death due to heart disease after radiotherapy for esophageal cancer","volume":"6","author":"Frandsen","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"2020052419000745300_ref9","first-page":"7389","article-title":"Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy","volume":"34","author":"Tamari","year":"2014","journal-title":"Anticancer Res"},{"key":"2020052419000745300_ref10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0360-3016(00)00685-4","article-title":"Fraction size and dose parameters related to the incidence of pericardial effusions: regarding Martel et al. IJROBP 40(1):155\u2013161; 1998","volume":"48","author":"Stavrev","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020052419000745300_ref11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13014-016-0590-1","article-title":"Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH)","volume":"11","author":"Aly","year":"2016","journal-title":"Radiat Oncol"},{"key":"2020052419000745300_ref12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(92)90304-D","article-title":"Late radiation response of canine mediastinal tissues","volume":"23","author":"Gillette","year":"1992","journal-title":"Radiother Oncol"},{"key":"2020052419000745300_ref13","article-title":"Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: a systematic review and meta-analysis","volume":"96","author":"Xu","year":"2017","journal-title":"Medicine"},{"key":"2020052419000745300_ref14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.radonc.2016.08.005","article-title":"Bayesian regression analysis of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer","volume":"121","author":"He","year":"2016","journal-title":"Radiother Oncol"},{"key":"2020052419000745300_ref15","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2012.02.015","article-title":"Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer","volume":"84","author":"Lin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020052419000745300_ref16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ijrobp.2015.03.030","article-title":"Expert consensus contouring guidelines for intensity modulated radiation therapy in esophageal and gastroesophageal junction cancer","volume":"92","author":"Wu","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020052419000745300_ref17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/61\/2\/298\/33292160\/rraa001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/61\/2\/298\/33292160\/rraa001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T23:00:28Z","timestamp":1590361228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/61\/2\/298\/5734977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,13]]},"published-print":{"date-parts":[[2020,3,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rraa001","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2020,2,13]]}}}